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Abstract 
Sox transcription factors play key regulatory roles throughout development, binding DNA through 
a consensus (A/T)(A/T)CAA(A/T)G sequence. Although many different Sox proteins bind to this se-
quence, it has been observed that gene regulatory elements are commonly responsive to only a small 
subset of the entire family, implying that regulatory mechanisms exist to permit selective DNA bind-
ing and/or transactivation by Sox family members. To identify and explore the mechanisms modu-
lating gene activation by Sox proteins further, we compared the function of Sox-2 and Sox-11. This 
led to the discovery that Sox proteins are regulated differentially at multiple levels, including trans-
activation, protein partnerships with Pit-Oct-Unc (POU) transcription factors, and DNA binding au-
toregulation. Specifically, we determined that Sox-11 activates transcription more strongly than Sox-
2 and that the transactivation domain of Sox-11 is primarily responsible for this capability. Addition-
ally, we demonstrate that the Sox-11 DNA binding domain is responsible for selective cooperation 
with the POU factor Brn-2. This requirement cannot be replaced by the DNA binding domain of Sox-
2, indicating that the DNA binding domain of Sox proteins is critical for Sox-POU partnerships. In-
terestingly, we have also determined that a conserved domain of Sox-11 has the novel capability of 
autoinhibiting its ability to bind DNA in vitro and to activate gene expression in vivo. Our findings 
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suggest that the autoinhibitory domain can repress promiscuous binding of Sox-11 to DNA and plays 
an important role in regulating the recruitment of Sox-11 to specific genes. 
 
The Sox family of transcription factors comprises a diverse group of proteins whose pat-
tern of expression is regulated both spatially and temporally (1). Sox factors are related by 
the homology (usually >50%) found within their high mobility group (HMG)1 DNA bind-
ing domains. Sox HMG domains have been found to bind to the consensus sequence 5′-
(A/T)(A/T)CAA(A/T)G-3′ in the minor groove of DNA (2). As the number of Sox proteins 
has grown to more than 20 members in multiple species, including both vertebrates and 
invertebrates, this family has been divided into seven subgroups, the members of which 
contain high homology within both the HMG domain and flanking regions (1). In some 
cases, subgroup members have similar patterns of expression during development and 
perhaps redundant functions. For example, the structurally similar group B members Sox-
1, -2, and -3 show overlapping expression in the fetal nervous system, and it has been sug-
gested that they perform similar functions (3, 4). Additionally, the group C members Sox-
4 and Sox-11 show high homology within their HMG domain and C-terminal tail, and they 
may also have complementary roles in the developing nervous system (5). 
The observation that the HMG DNA binding domains of many members of the Sox 
family bind a consensus sequence has prompted the question of whether there are selective 
mechanisms in place to recruit a specific Sox protein to a gene regulated by an HMG bind-
ing site. A review of the literature reveals that genes rely on a diverse array of mechanisms 
to regulate DNA binding among members of other transcription factor families, which 
may also apply to Sox proteins. A particularly intriguing example of DNA binding regu-
lation has been found within multiple members of the Ets family. First characterized in 
Ets-1, the affinity of these proteins for DNA is tightly regulated by autoinhibitory regions 
flanking the DNA binding domain (6, 7). Interestingly, the ubiquitous HMG-1 and HMG-
2 proteins employ a similar regulatory strategy whereby their highly acidic C-terminal tails 
are capable of negatively affecting the ability of those proteins to bind DNA (8). Im-
portantly, although the autoinhibitory domains of both Ets and HMG proteins repress 
DNA binding, they can be neutralized by post-translational modification or by interaction 
with partner proteins, which allows their recruitment to be exquisitely regulated in a gene-
specific manner (7, 9–12). 
Although specific evidence of DNA binding autoregulation has not yet been observed 
in Sox proteins, it is clear that cis-regulatory elements are capable of selecting specific Sox 
transcription factors. Attempts to uncover the mechanisms through which Sox specificity 
is achieved have revealed that recruitment often requires proper interaction with other 
transcription factors at adjacent binding sites on the DNA. This is illustrated by one of the 
cis-regulatory elements that control expression of the fibroblast growth factor 4 (FGF-4) 
gene in embryonal carcinoma cells. FGF-4 expression depends on a distal enhancer (13, 14), 
which contains an essential binding site for Sox-2 (15–17). However, Sox-2 does not appear 
to be  capable of substantial activation of this gene on its own, but rather requires cooper-
ation with the POU transcription factor Oct-3 (18, 19). The presence of Oct-3 at a site adja-
cent to Sox-2 promotes cooperative DNA binding, resulting in a synergistic increase in 
transactivation (18, 19). The partnership of Sox-2 and Oct-3 is extremely specific for these 
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two proteins because it requires stereospecific alignment and protein-protein interaction 
between the HMG and POU DNA binding domains when Sox-2 and Oct-3 are present at 
their adjacent binding sites (18). Additionally, the role of Oct-3 cannot be fulfilled by Oct-
1 for the FGF-4 enhancer, indicating that only certain Sox-POU combinations can lead to 
productive regulation of a particular gene (15). Specific partnerships have also been ob-
served among other members of the Sox and POU families. Utilizing the binding sequence 
found in the FGF-4 enhancer, it was determined that Sox-10 specifically partners with Oct-
6, and Sox-11 cooperates optimally with the POU factors Brn-1 and Brn-2 (20, 21). These 
observations have led to the hypothesis that a Sox-POU combinatorial code may exist as a 
mechanism of transcriptional regulation (20). 
Although significant progress has been made in understanding the differential function 
of Sox proteins, both on their own and in combination with other factors, little is known 
about the mechanisms involved. To elucidate the mechanisms through which Sox proteins 
may be regulated, we initiated a functional comparison of Sox-2 and Sox-11 using pro-
moter/reporter gene constructs that contain HMG and POU binding sites. Through this 
study, we determined that Sox-2 performs very differently than Sox-11, being a much 
weaker transactivator, while at the same time binding more strongly to DNA in vitro. To 
understand the mechanisms involved in the functional differences between Sox-2 and Sox-
11, we addressed three questions. First, what role does each of the domains of Sox-2 and 
Sox-11 play in differential gene activation? Second, how specific are Sox-2 and Sox-11 part-
nerships with POU proteins, and which regions of Sox-2 and Sox-11 are important for Sox-
POU partnerships? Third, which domain(s) are critical for the decreased DNA binding of 
Sox-11 compared with Sox-2? 
We have addressed these questions using Sox deletion mutants and Sox-2/11 chimeric 
proteins created by interchanging the N terminus, HMG DNA binding domain, or C ter-
minus of both proteins. These studies led to the discovery that the C-terminal transactiva-
tion domains play the primary role in the differential capability of Sox-2 and Sox-11 to 
transactivate. Additionally, we determined that Sox-11, but not Sox-2, can cooperate with 
Brn-2 and that the Sox-11/Brn-2-specific cooperation requires both adjacent binding of the 
two factors to DNA and the HMG domain of Sox-11. Therefore, this study further supports 
the hypothesis that a Sox-POU combinatorial code exists (20) and suggests that this inter-
action code is dependent on the HMG domain of the Sox protein involved. Finally, we also 
identified a novel domain within a conserved region of Sox-11 which is capable of nega-
tively regulating both its ability to bind DNA in vitro and activate gene expression in vivo. 
Together, this work significantly enhances our understanding of the mechanisms that in-
fluence selective recruitment of Sox proteins through partner specificity and DNA binding 
autoregulation. 
 
Experimental Procedures 
 
Plasmids 
Constructs pCATSO3, pCMVSox-2F1–180, pCMVSox-2, pCMVOct-3, pCMVOct-1, and CMV-
β-gal have been described previously (19). The promoter/reporter construct pCATDC3 was 
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constructed similarly to pCATSO3 as follows. Complementary oligonucleotides (synthe-
sized by the Eppley Cancer Institute Molecular Biology Core Facility) containing two sets 
of the HMG site from the DC5 enhancer site and the POU binding sites (in boldface) from 
the FGF-4 enhancer region and BamHI sites at both ends (5′-GATCCTCATTGTTGTG 
ATGCTAATGGCTCATTGTTGTGATGCTAATGGAG-3′) were annealed and ligated to 
generate multimers. Differences in the DC5 and FGF-4 HMG binding sequence are under-
lined. These multimers were then ligated into a BglII site upstream from the SV40 promoter 
of the pCAT vector (Promega) to generate pCATDC3, which contains a total of six tandem 
copies of the HMG and POU sites. Similarly, pCATS4 contains a total of four tandem copies 
of the FGF-4 HMG site and was made using identical primers as pCATSO3, with the ex-
ception of a scrambled POU site. The upper primer is as follows with the HMG and scram-
bled POU sites in bold: (5′-GATCTCTTTGTTTGGCGGATCAT GGCTCTTTGTTTGG 
CGGATCATGGA-3′). 
The plasmids pCMVSox-11 and pCMVBrn-2 were gifts from Michael Wegner (20). Sox-
11F was constructed using the primers FLAGSox-11 (5′-CGTGCTGGTACCGCCAC-
CATGGACTACAAGGACGACGATGATATGGTGCAGCAGGCCGAGAGC-3′) and Sox-
11/395 (5′-GCTGGATCCGACCGCCACGACTGCCTCCCG-3′) to amplify the coding re-
gion from CMV5-Sox-11. This PCR incorporated the FLAG epitope sequence, preceded by 
a Kozak sequence and a KpnI site, onto the 5′-end of the coding region of Sox-11 and a 
BamHI site at the 3′-end. The KpnI/BamHI sites were then digested and the Sox-11F se-
quence ligated into the KpnI/BamHI sites of the CMV5 expression vector. The Sox-2F ex-
pression plasmid referred to in this report was constructed by removing the Sox-2F 
sequence from the pCEP4 vector (19) using the KpnI/BamHI sites and relegating the Sox-
2F sequence into the same sites present in CMV5. 
Site-directed mutagenesis or deletions were carried out using a modification of the 
QuikChange (Stratagene, La Jolla, California) method. All amino acid numbers are based 
on the wild-type Met being defined as 1, not the Met included with the FLAG tag. Briefly, 
two primers, complementary to the sequence flanking the targeted region and to each 
other, were used in PCR amplification of the entire plasmid, thus modifying the indicated 
template. Unless otherwise noted, each of the primers identified herein represents the 
sense strand of a perfectly complementary pair of primers used during PCR. To begin the 
construction of the Sox-2/11 chimeras, unique restriction sites were incorporated at the 
N-terminal and C-terminal flanks of the HMG box of both the Sox-2F and Sox-11F plasmid. 
Sites were chosen in such a way that little alteration would be made to the wild-type 
coding sequence. Mutagenesis to include a NheI site was performed with either the 
sox2mut1 (5′-GGCAACCAGAAGAATGCTAGCCCGGAACGTGTCAAGAGGCCC-3′) or 
sox11mut1 (5′-CCGGACTGGTGCAAGACGGCTAGCGGCCACATCAAACG-3′) primer 
pair. The NheI alteration added a Ser following Ala-39 of Sox-2F but did not affect the cod-
ing sequence of Sox-11F. The products of these PCR reactions were then used in a second 
round of mutagenesis to include a NotI site using either the sox2mut2 (5′-GTACAC-
GCTTCCCGCGGCCGCTTTGCTCGCCCCCGG-3′) or sox11mut2 (5′-GCCAAGCCCAG 
CGCGGCCGCACAGAGCCCGGACAAGAGC-3′) primer pair. This replaced Gly-131 and 
Gly-132 of Sox-2F as well as Ala-134 and Gly-135 of Sox-11F with the amino acids Ala-Ala-
Ala. This cloning resulted in Sox-2F double mutant and Sox-11F double mutant, each of 
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which contained a KpnI and BamHI site at their extreme 5′- and 3′-ends, respectively, as 
well as an NheI and NotI site at the 5′- and 3′- respective ends of their HMG boxes. These 
sites made it possible to use standard restriction digests and ligations to interchange either 
the N-terminal, HMG, or C-terminal region of Sox-2F with the corresponding region of 
Sox-11F, resulting in the creation of the chimeric plasmids Sox-11-2-2F, -11-11-2F, -2-11-2F, 
-2-11-11F, -2-2-11F, and -11-2-11F. 
To create Sox-11FΔTAD, the primer pair sox11Δtad (5′-CTCTACTACAGCTTCAAGTG 
AGCGGCCGCAAACATCACCAAGCAGCAG-3′) was used to incorporate a stop codon 
following Lys-282 of Sox-11F. The Sox-11F and Sox-11FΔTAD expression constructs were 
then used as the templates to create Sox-11FΔAR and Sox-11FΔARΔTAD, respectively, us-
ing the primer pairs of sox11Δar (5′-GCCAAGGTGGTCTTCCTGGACGCGCAGCAG-
CAACCCCCTCAG-3′) to delete amino acids 190–223. To facilitate in vitro translation of the 
various Sox proteins, the coding regions from each of the above CMV5-derived vectors 
were cloned into the KpnI/BamHI sites of pCRScript (Stratagene), downstream from the T7 
promoter. The identity of all plasmids modified by PCR-based mutagenesis as well as 
pCATS4 and pCATDC3 was verified by sequence analysis at the Eppley Cancer Institute 
Molecular Biology Core Facility. 
 
Cell Culture and Transient Transfection 
HeLa cells were maintained and transfected using the calcium phosphate precipitation 
method as described previously (19). All transfections were performed in triplicate with 
representative experiments shown. Plasmid DNA was isolated and purified using Qiagen 
tip-500 columns. 
 
Extract Preparation and Western Blotting 
HeLa cells were transfected with 5 μg of the relevant plasmids as described above, and 
extracts were prepared 2 days post-transfection. Whole cell protein extracts were prepared 
as described previously (19). Nuclear extracts were prepared using the NE-PER kit (Pierce) 
following the manufacturer’s protocol. The isolated nuclei from ~6–7 × 106 cells were lysed 
in 100 μl of nuclear extraction reagent supplemented with various protease and phospha-
tase inhibitors (22). When preparing Sox-11F, Sox- 11FΔTAD, and Sox-11FΔARΔTAD for 
the nuclear extracts used in the electrophoretic gel mobility shift assay (EMSA) shown in 
figure 6c, calpain inhibitor I was added to the growth media 4 h before lysis and was in-
cluded in the extraction buffer to minimize degradation caused by potential proteasome 
activity. Extracts were stored at –80°C. Sox proteins produced through in vitro transcrip-
tion and translation were made using the T7 Quick Coupled Rabbit Reticulocyte Lysate 
(Promega) transcription/translation system. 
Western blotting was performed using 10 μl of in vitro translated lysate or nuclear lysate 
from 5 × 105 transfected HeLa cells as described (19) using the anti-FLAG M2 antibody 
(Sigma). Proteins were detected using the enhanced chemifluorescence (ECF) kit (Amer-
sham Biosciences) and scanned on a Storm PhosphorImager (Molecular Dynamics). Quan-
titation was performed using the ImageQuant 5.0 analysis software (Molecular Dynamics). 
Western blots were performed in duplicate or triplicate with representative blots shown. 
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EMSA 
Gel mobility shift analysis was based on the method of Fried and Crothers as modified by 
this laboratory (23). Complementary oligodeoxynucleotide probes were annealed for each 
probe or competitor, and the resulting double-stranded oligodeoxynucleotide probes were 
labeled with [α-32P]dCTP by Klenow fill-in reaction of the single-stranded regions at the 
end of each double-stranded oligodeoxynucleotide probe (lowercase bases). The wild-type 
Sox probe (hmg1) contained a single HMG binding site (bold), which was based on the 
sequence present in the FGF-4 enhancer, whereas in the mutant Sox probe (HMGmut) this 
sequence is scrambled (underlined). The sequence of hmg1 (sense strand) is 5′-tagaAAA 
CTCTTTGTTTGCCATGTCG-3′, and the sequence of HMGmut (sense strand) is 5′-tagaA 
AATTAGTCGAATGCCATGTC-3′. The hmg2 probe was created to mimic the pCATSO3 
reporter construct in that it contains multiple HMG binding sites separated by 14bp. The 
sequence of hmg2 (sense strand) is 5′-tagaTCTTTGTTTGGCGGATCATGGCTCTTTGTT 
TGGCGGATCATGGA-3′. For gel mobility shift and competition assays, 1–2 μl of nuclear 
lysate or 3–4 μl of in vitro translated protein was incubated (at room temperature) for 30 
min in a 20-μl volume containing 20 mM HEPES pH 7.6, 1 mM EDTA, 2 mM MgCl2, 20% 
glycerol, 50 mM NaCl, 5 μg of bovine serum albumin, 5 μg of p(dGdC)p(dGdC), and 20,000 
cpm of labeled probe (final concentration of 0.5–1 nM) with or without competitor. The 
exact volume of nuclear lysate used in each assay was determined by first normalizing for 
differences in Sox protein concentration based on Western blot analysis. In gel mobility 
supershift assays, reaction mixtures were incubated for 1 h at 4°C with the indicated anti-
body before addition of the probe, after which the reaction was continued at room temper-
ature for 30 min. Immediately after the completion of binding, the reactions were electro-
phoresed on a nondenaturing 4% Tris-glycine polyacrylamide gel for 4 h at 150V. The gels 
were then dried and exposed to a PhosphorImager screen for 1–7 days before scanning on 
a Storm PhosphorImager. Quantitation of band intensities was performed using the Im-
ageQuant 5.0 analysis software. Experiments using hmg2 (see fig. 6, b and c) were also 
performed with hmg1 with the same trend in binding intensity between the Sox-11 mu-
tants. All aspects of each mobility shift assay were repeated and similar results were ob-
tained. 
 
Results 
 
Functional Comparison of Sox-2 and Sox-11 
The initial goal of this study was to elucidate the mechanisms permitting selective recruit-
ment and activation by specific Sox proteins at a particular gene. To address this issue, we 
compared the function of Sox-2 with the related transcription factor Sox-11. These proteins 
were selected for several reasons. First, the gross domain structure of each has been stud-
ied, revealing the location of the DNA binding domain and transactivation domain of each 
protein (4, 19, 20). Second, to understand the function of a transcription factor in vivo, it is 
best studied in a model system using a known binding sequence from a regulated gene. 
The binding site for Sox-2 within the enhancer of the FGF-4 gene has been determined and 
provides an excellent model system (15, 16). Thus far, target genes of Sox-11 have not been 
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identified; however, the FGF-4 enhancer sequence has also been utilized in a partial char-
acterization of Sox-11 (20), indicating that it may provide a relevant system in which to 
study this transcription factor. Finally, the expression pattern of Sox-2 and Sox-11 within 
the developing nervous system overlaps, leading to the postulate that there are cell types 
in which some genes may be regulated differentially depending on whether Sox-2 or Sox-
11 binds to a cis-regulatory element (24). 
To compare Sox-2 and Sox-11 functionally, we assayed their ability to activate the 
pCATSO3 promoter/reporter gene construct in HeLa cells, which do not contain any 
known Sox-like activity (15, 19). The pCATSO3 plasmid contains six tandem repeats of a 
24-bp region of the FGF-4 enhancer upstream from an SV40 promoter driving the expres-
sion of a chloramphenicol acetyltransferase (CAT) reporter gene. A promoter/reporter con-
struct containing multiple HMG binding sites was necessary for these studies because gene 
activation by either Sox-2 or Sox-11 via a single HMG site did not rise above the basal 
expression of the promoter/reporter gene construct (data not shown). The 24-bp region 
contains both the HMG binding site and POU binding site found in the FGF-4 enhancer. 
The pCATSO3 construct was employed to perform a functional comparison of Sox-2 and 
Sox-11 because it has been used previously to identify the transactivation domain of Sox-
2 and to identify p300 as a potential coactivator of Sox-2 activity (19). Furthermore, a very 
similar construct, also containing the HMG/POU enhancer sequence of the FGF-4 gene, 
was utilized in the initial characterization of Sox-11 (20). 
For the functional comparison of Sox-2 and Sox-11, HeLa cells were transiently trans-
fected with pCATSO3 and increasing concentrations of expression plasmid encoding ei-
ther Sox-2F or Sox-11F, each tagged at their N terminus with a FLAG epitope. This revealed 
that Sox-11F is a much more potent activator of the pCATSO3 promoter/reporter gene con-
struct than Sox-2F (fig. 1a). At all concentrations tested, transfection of Sox-11F led to 40–
75-fold more reporter gene activity than Sox-2F. This experiment was also repeated with 
Sox-2 and Sox-11 expression constructs without FLAG epitopes, and no differences were 
observed between the ability of the tagged and untagged proteins to transactivate (data 
not shown). Additionally, to verify that the functional differences observed between Sox-
2F and Sox-11F were not caused by variations in protein expression, Western blot analysis 
was performed on nuclear extracts of transfected HeLa cells using the anti-FLAG M2 anti-
body. This analysis revealed that there was little difference between Sox-2F and Sox-11F 
expression in the nucleus (fig. 1b). In fact, in multiple experiments, we found that Sox-11F 
expression was consistently lower than Sox-2F. Thus, the difference in transactivation ca-
pability between Sox-2F and Sox-11F (fig. 1a) may be an underestimate. 
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Figure 1. Transactivation potency and protein expression of Sox-2F and Sox-11F. a and c, du-
plicate plates of HeLa cells were transfected with 5 μg of pCATSO3 and increasing 
amounts of plasmid expressing Sox-2F, Sox-11F, or Oct-3, as indicated. Results are shown 
as the relative CAT expression assayed in each transfection compared with the pCATSO3 
reporter alone. The error bars represent the S.D. between the CAT activity of the duplicate 
plates assayed. All transfections included empty CMV5 plasmid to ensure that the final 
amount of DNA was equivalent. CMV-β-gal was also included to normalize for potential 
differences in transfection efficiency. Each experiment was repeated at least three times 
with a representative example shown. b, expression of Sox-2F and Sox-11F was deter-
mined by Western blot analysis of nuclear extracts obtained from transfected HeLa cells. 
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The presence of each Sox protein was detected using the anti-FLAG M2 antibody, visual-
ized using ECF, and quantitated using a Storm PhosphorImager and ImageQuant 5.0 soft-
ware. The molecular masses are shown on the left of the blot. 
 
Our observation that Sox-11F was such a potent activator on its own led us to question 
whether an endogenous POU factor could be binding at the adjacent site and assisting in 
Sox-11F-mediated activation. This is an important question because Sox-2 requires the 
partner Oct-3 for activation. Thus, if Sox-11 can activate significantly without a partner, it 
would imply that a key functional difference exists between these two proteins. To test 
this, we constructed the promoter/reporter construct pCATS4, which is similar to 
pCATSO3 except that the POU site has been scrambled, and there are only four HMG sites 
in the promoter. When activation of pCATS4 by Sox-2F and Sox-11F is compared with 
pCATSO3 it is clear that Sox-11F can activate strongly in a partner-independent manner, 
whereas Sox-2F requires the adjacent POU site and binding of Oct-3 for significant activa-
tion (fig. 1c). 
To understand further the function of Sox-2 and Sox-11, we examined how each of the 
individual domains of these two proteins contributes to their different abilities to transac-
tivate. For this purpose, we divided Sox-2 and Sox-11 into three regions: the N-terminal 
region, the HMG DNA binding domain, and the region C-terminal to the DNA binding 
domain. The N-terminal regions of both proteins contain ~40 amino acids, with no known 
function in either protein. The HMG DNA binding domains of Sox-2 and Sox-11 are 65% 
identical and consist of 79 amino acids. The C-terminal regions of both Sox-2 and Sox-11, 
which are known to contain modular transactivation domains (4, 19, 20), consist of 189 and 
265 amino acids, respectively. To determine the role of each of these regions, we created 
chimeric proteins by interchanging the N-terminal portion, the HMG box (including ~10 
amino acids of the C-terminal flanking sequence), or the C-terminal portion of Sox-2 and 
Sox-11 in all possible combinations. We hypothesized that if one or more of these regions 
of Sox-11F were responsible for its strong transactivation, placing them into Sox-2F should 
convert Sox-2F into a strong transactivator. These chimeras were created by first using PCR 
mutagenesis to insert unique restriction enzyme sites on either side of the plasmid se-
quence encoding the HMG domain of both proteins. These novel sites were designed to 
allow for minimal perturbation of the wild-type amino acid sequence, and we determined 
that they had no effect, either functionally or in protein expression, on Sox-2F or Sox-11F 
(data not shown). The presence of these unique sites within Sox-2F and Sox-11F allowed 
us to interchange each domain by restriction digestion and in-frame religation, resulting 
in six chimeras (fig. 2). The expression level and expected molecular mass of the chimeric 
proteins were determined by Western blot analysis (fig. 2). Some differences in the level of 
chimeric protein expression were apparent; for example, the average expression of the con-
structs containing the Sox-2 C terminus was ~3-fold higher than those containing the Sox-
11 C terminus. However, normalizing for these differences during our functional analysis 
does not affect our conclusions (see below). 
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Figure 2. Transactivation potency and protein expression of Sox- 2/11 chimeras. Top panel, du-
plicate plates of HeLa cells were transfected with 5 μg of pCATSO3 and 100 ng of plasmid 
expressing the indicated Sox chimera. Results are shown as the relative CAT expression 
assayed in each transfection compared with the pCATSO3 reporter alone. The error bars 
represent the S.D. between the CAT activity of the duplicate plates assayed. Bottom panel, 
expression of chimeras was determined by Western blot analysis of whole cell extracts 
obtained from transfected HeLa cells. The presence of each Sox protein was detected us-
ing the anti-FLAG M2 antibody, visualized using ECF, and quantitated using a Storm 
PhosphorImager and ImageQuant 5.0 software. The molecular mass is shown on the left 
of the blot. All transfections included empty CMV5 plasmid to ensure that the final 
amount of DNA was equivalent. CMV-β-gal was also included to normalize for potential 
differences in transfection efficiency. Each experiment was repeated at least three times 
with a representative experiment shown. 
 
The ability of each of the chimeras to activate pCATSO3 was then compared with that 
of Sox-2F and Sox-11F to determine the role of each region in gene activation (fig. 2). 
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Clearly, there are striking differences in transactivation capabilities between the chimeras 
containing the C-terminal region of Sox-2F (Sox-11-2-2F, -11-11-2F, and -2-11-2F) and those 
containing the C-terminal region of Sox-11F (Sox-2-11-11F, -2-2-11F, and -11-2-11F). For 
example, when the C terminus of Sox-2F is replaced with that of Sox-11F (Sox-2-2-11F) the 
chimeric protein is capable of activating gene expression 20-fold higher than Sox- 2F. More-
over, in the reciprocal chimera, replacing the C-terminal region of Sox-11F with that of Sox-
2F (Sox-11-11-2F) resulted in a 30-fold decrease in transactivation capability. Hence, we 
conclude that the domain primarily responsible for the functional difference between Sox-
2F and Sox-11F lies in their C-terminal regions, which are known to contain their respective 
transactivation domains (19, 20). As mentioned above, because those chimeras containing 
the Sox-11 C terminus are less abundant (as determined by Western blot analysis) but ex-
hibit stronger reporter gene activation, normalization to relative protein levels would not 
alter this conclusion. 
Next, we addressed the role of the HMG domain or N terminus in gene activation. When 
either of these domains is interchanged within those chimeras containing the Sox-2F C ter-
minus, the reporter gene expression is so low that no significant differences can be meas-
ured. However, it is apparent that both of these regions play a functional role when the 
chimeras containing the Sox-11F C terminus are considered (fig. 2). Comparison of either 
Sox-11F with Sox-11-2-11F or Sox-2-11-11F with Sox-2-2-11F reveals a decrease in activa-
tion of ~2.5- fold in each case, indicating that the HMG domain of Sox-11F contributes to 
stronger potentiation compared with the HMG domain of Sox-2F. A similar consideration 
of the chimeras containing the N-terminal rearrangements demonstrates that the N termi-
nus of Sox-2F enhances transactivation ~2-fold (compare Sox-11F and Sox-2-11–11F, or Sox-
2-2-11F and Sox-11-2-11F). These findings demonstrate that the N terminus and HMG do-
mains of these Sox proteins make a contribution to their ability to activate transcription. 
 
Domain Requirements in Sox-POU Partnerships 
Although understanding the properties of a transcription factor on its own is important, it 
is also critical to understand its ability to work in conjunction with other transcriptional 
regulators. Indeed, it is widely recognized that many Sox proteins, including Sox-2 and 
Sox-11, can activate transcription synergistically when bound to DNA adjacent to specific 
members of the POU family of transcription factors (15, 19, 21, 25). The observation that 
the HMG and POU domains of Sox-2 and Oct-3 are capable of direct interaction (18) sug-
gests that functional Sox-POU partnerships may depend on a selective interaction between 
their DNA binding domains. To test this possibility, we compared the ability of Sox-2, Sox-
11, and the Sox-2/11 chimeras to cooperate with various POU proteins in transcriptional 
activation and determined which domains are required for cooperation. 
To study the selective nature of Sox-POU cooperation, HeLa cells were transfected with 
either Sox-2 or Sox-11 and the POU proteins Oct-3 or Brn-2 and then assayed for the ability 
of each combination to activate the pCATSO3 promoter/reporter gene construct. We first 
tested the effect of escalating doses of Oct-3 on the ability of Sox-11 to transactivate. Although 
Sox-11 is known to cooperate with Brn-2 (20), it was unknown how it would respond in 
the presence of Oct-3. This study demonstrated that Sox-11 is capable of synergistically 
activating gene expression with Oct-3 (fig. 3a), indicating that it cooperates with this POU 
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factor similarly to Sox-2 (18, 19). To ascertain whether Oct-3 could be cooperating with Sox-
11 by up-regulating Sox-11 protein expression, we performed Western blot analysis on du-
plicate samples of cells transfected with Sox-11F in the presence or absence of Oct-3 and 
quantitated the expression of Sox-11F (fig. 3c). This demonstrated that Oct-3 had little effect 
on Sox-11 expression. Finally, we examined whether Brn-2 could partner with both Sox-11 
and Sox-2. Interestingly, we determined that Sox-11, but not Sox-2, cooperates with Brn-2 
to activate transcription (fig. 3b). This selective partnership further supports the hypothesis 
that restrictive mechanisms are in place that allow only specific Sox-POU combinations to 
cooperate in transcriptional activation. 
 
 
 
Figure 3. Sox-2 and -11 cooperate with Oct-3, but only Sox-11 partners with Brn-2. HeLa cells 
were transfected with 5 μg of pCATSO3 and the indicated amounts of expression plas-
mids. a, Sox-11F was transfected with increasing doses of Oct-3. b, Sox-2F or Sox- 11F was 
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transfected with increasing doses of Brn-2. Results are shown as the relative CAT expres-
sion assayed in each transfection compared with the pCATSO3 reporter alone. The error 
bars represent the S.D. between the CAT activity of the duplicate plates assayed. All trans-
fections included empty CMV5 plasmid to bring the final amount of DNA to 10 μg. CMV-
β-gal was also included to normalize for potential differences in transfection efficiency. 
Each experiment was repeated at least three times with a representative example shown. 
c, expression of Sox-11F was determined by Western blot analysis of whole cell extracts 
obtained from two separate transfections of HeLa cells with 1 μg of each of the indicated 
expression plasmids. Sox-11F protein was detected using the anti-FLAG M2 antibody, 
visualized using ECF, and quantitated using a Storm PhosphorImager and ImageQuant 
5.0 software. Molecular mass is shown at the left of the blot, and the relative intensities of 
Sox-11F bands are shown below. All transfections included empty CMV5 plasmid to en-
sure that the final amount of DNA was equivalent. CMV-β-gal was also included to nor-
malize for potential differences in transfection efficiency. This experiment was repeated 
three times with a representative example shown. 
 
To begin to elucidate the mechanism underlying the Sox-11/Brn-2 selective partnership, 
we first examined whether Brn-2 needed a POU binding site adjacent to the HMG site to 
cooperate with Sox-11 in gene activation. This was addressed by assaying the ability of 
Sox-11 and Brn-2 to activate pCATS4, in which the POU site is scrambled. In this experi-
ment, we found that removal of the POU site completely abrogates Sox-11/Brn-2 coopera-
tion (fig. 4a). This indicates that the enhancement of Sox-11 activation by Brn-2 requires 
that they be located at adjacent sites on the DNA and is not the result of a general up-
regulation of Sox-11 protein expression. Next, we examined which domains are needed for 
these partnerships. Previous studies using Oct-3/1 chimeric proteins have determined that 
the Oct-3 POU domain is necessary for its cooperation with Sox-2 on the FGF-4 enhancer 
sequence. When the POU domain of Oct-3 is exchanged with that of Oct-1, the resulting 
Oct-3-1-3 protein can no longer synergize with Sox-2 (26). The creation of the Sox-2/11 chi-
meric proteins provided us with a similar system in which to isolate the domain of Sox-11 
which permits selective cooperation with Brn-2. To test this possibility, we compared the 
ability of Sox-2-11-2F and Sox-11-2-11F to transactivate in the presence of Brn-2 (fig. 4b). 
This study reveals that by interchanging the HMG domain of Sox-2 with that of Sox-11, the 
chimeric protein Sox-2-11-2F is able to cooperate functionally with Brn-2 in a dose-depend-
ent manner. This is observed in the Brn-2 dependent increase in Sox-11F and Sox-2-11-2F 
activity above that seen with each protein alone. The importance of the Sox-11 HMG do-
main is supported further by the fact that when Sox-11-2-11F is transfected in combination 
with Brn-2 no cooperative activation is detected above the activity of Sox-11-2-11F alone. 
Thus, we demonstrated that the cooperation of Sox-11 with Brn-2 appears to be dependent 
on the HMG domain of Sox-11 as well as adjacent binding of the two proteins. 
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Figure 4. Adjacent binding sites and the Sox-11 HMG domain are required for cooperation with 
Brn-2. a, duplicate plates of HeLa cells were transfected with 5 μg of pCATS4 and 100 ng 
of Sox-11F, Brn-2, or 100 ng of both as indicated. b, duplicate plates of HeLa cells were 
transfected with 5 μg of pCATSO3 and 100 ng of Sox chimera expression vector with 0, 
100, or 500 ng of Brn-2 expression vector. Results are shown as the relative CAT expres-
sion assayed in each transfection compared with the pCATS4 or pCATSO3 reporter alone. 
The error bars represent the S.D. between the CAT activity of the duplicate plates assayed. 
All transfections included empty CMV5 plasmid to bring the final amount of DNA to 10 
μg. CMV-β-gal was also included to normalize for potential differences in transfection 
efficiency. Each experiment was repeated at least three times with a representative exper-
iment shown. 
 
In Vitro DNA Binding of Sox-2 and Sox-11 
Binding of Sox transcription factors to DNA has been demonstrated to be an essential and 
often highly regulated step in their role as transcriptional activators (18, 25, 27–29). With 
multiple examples of binding regulation within the Sox family and an indication that the 
HMG DNA binding domains of Sox-2 and Sox-11 have variable effects on selective POU 
partnerships as shown by our chimeric studies, we examined whether there are differences 
in the in vitro DNA binding capabilities of Sox-2 and Sox-11. To accomplish this goal, HeLa 
cells were transfected with either Sox-2F or Sox-11F, and nuclear extracts were prepared 
for use in EMSA to measure the ability of each Sox protein to bind a radiolabeled probe 
(hmg1) containing a single HMG binding sequence. In each EMSA, the concentration of 
Sox protein included was first normalized after quantitation by Western blot analysis. 
When in vitro DNA binding of Sox-2F is compared with Sox-11F, a single complex was 
observed with Sox-2F, whereas little or no binding was detected with Sox-11F (fig. 5a). The 
Sox-2F complex was partially supershifted specifically with the M2 antibody and com-
peted by excess, unlabeled wildtype probe, but not a probe in which the HMG site has 
been scrambled (fig. 5a). In contrast, we detected little or no binding of full-length Sox-11F 
despite our attempts to use multiple binding buffers, different nonspecific competitors, or 
lower ionic strength electrophoresis conditions (data not shown). To examine roles of the 
HMG domains of Sox-2F and Sox-11F in mediating their differences in DNA binding, an 
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EMSA of the Sox chimeras in which the HMG domains were interchanged was also per-
formed (fig. 5b). Surprisingly, Sox-2-11-2F was capable of binding the DNA probe with an 
intensity similar to that of Sox-2F, whereas DNA binding by Sox-11-2-11F was not detected. 
Thus, the region(s) responsible for differential DNA binding between Sox-2F and Sox-11F 
lies outside of the HMG domain. 
 
 
 
Figure 5. In vitro DNA binding of Sox proteins. a, equal amounts of Sox-2F or Sox-11F pro-
tein obtained from transfected HeLa cells were studied by EMSA with radiolabeled hmg1 
probe. To determine binding specificity, excess unlabeled wild-type or mutant probe was 
included in the binding reaction as indicated. Supershift analysis was performed by incu-
bating the binding reaction for 1 h at 4°C with either anti-FLAG M2 antibody or an equal 
amount of nonspecific mouse IgG antibody before adding the probe. b, equal amounts of 
the indicated Sox protein obtained from transfected HeLa cells were studied by EMSA 
with radiolabeled hmg1 probe. The EMSA gel was exposed to a PhosphorImager cassette 
for detection and quantification using a Storm PhosphorImager and ImageQuant 5.0 soft-
ware. Each aspect of these experiments was repeated at least twice using multiple prepa-
rations of nuclear extract. The position of the free probe in the gel is indicated by F. 
 
Investigation of the DNA Binding Autoregulation of Sox-11 
The observation that region(s) of Sox-11 beyond its HMG domains may repress DNA bind-
ing led us to hypothesize that a domain capable of autoinhibiting Sox-11 exists in this pro-
tein. To determine whether an autoinhibitory region exists within Sox-11, deletion 
constructs were made and tested for their ability to bind DNA. Our deletion strategy fo-
cused on two acidic regions within the C terminus, which were particularly intriguing be-
cause of the acidic nature of autoinhibitory regions isolated in other proteins (8, 30–33). 
The distal region (amino acids 283–395) contains an acidic/hydrophobic region known to 
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contain the transactivation domain (TAD) (20), while the central region (amino acids 189–
224) contains a highly acid-rich (AR) set of amino acids (20/27 consecutive residues being 
Asp or Glu). The AR region of Sox-11 cannot act as a TAD (20),2 nor does it have any other 
known function. 
To study each of these regions, three Sox-11F deletion constructs (fig. 6a) were placed in 
vectors allowing protein production either through in vitro translation (fig. 6b) or in HeLa 
cells (fig. 6c). For these studies, protein production was determined by Western blot anal-
ysis (fig. 6b, top), and a similar amount of each Sox-11F deletion construct was included in 
the binding reaction (fig. 6b, bottom). After protein normalization, the DNA binding capa-
bility of the Sox-11F deletion mutants was determined by EMSA. This was accomplished 
using either the hmg1 or the hmg2 probe, which contains two HMG sites separated by 14 
bp. The experiments performed with hmg2 revealed the same trend in binding intensity 
between the Sox-11 mutants as the hmg1 probe (data not shown). Our examination of the 
DNA binding ability of in vitro translated Sox proteins revealed that identical to our obser-
vations from HeLa cell extracts, Sox-2F binding was much stronger that Sox-11F (fig. 6b, 
compare lanes 2 and 3) despite similar protein expression. Interestingly, when the AR re-
gion is removed from Sox-11F, the protein binds well to the radiolabeled probe (lane 4). 
Furthermore, although some binding by Sox-11FΔTAD is observed (lane 5), it is also en-
hanced upon removal of the central AR region (lane 6). These results indicate that the AR 
region of Sox-11 can inhibit DNA binding of in vitro translated protein. 
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Figure 6. Identification of autoregulatory regions within Sox-11. a, diagram of Sox-11F deletion 
constructs. Sox-11F represents the full-length protein (amino acids 1–395). Amino acids 
190–223 were deleted from Sox-11FΔAR. Amino acids 283–395 were deleted from Sox-
11FΔTAD. Amino acids 190–223 and 283–395 were deleted from Sox-11FΔARΔTAD. b, 
top, Western blot analysis of the in vitro translated Sox proteins. The presence of each Sox 
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protein was detected using the M2 antibody, visualized using ECF detected by a Storm 
PhosphorImager, and quantified using ImageQuant 5.0 software. The molecular mass is 
shown on the left of the blot. Bottom, equal amounts of in vitro translated Sox-2F, Sox-11F 
protein, or the indicated deletion construct were studied by EMSA with radiolabeled 
hmg2 probe. c, equal amounts of Sox-11F protein or the indicated deletion construct pro-
duced in HeLa cells were studied by EMSA with radiolabeled hmg2 probe. Supershift 
analysis was performed by incubating the binding reaction for 1 h at 4°C with either anti-
FLAG M2 antibody or an equal amount of nonspecific mouse IgG antibody before adding 
the probe. The EMSA gels were exposed to a PhosphorImager cassette for detection using 
a Storm PhosphorImager and quantified using ImageQuant 5.0 software. Each aspect of 
these experiments was repeated at least twice using multiple preparations of extract. The 
position of the free probe in the gel is indicated by F. 
 
To determine whether the AR region is able to repress DNA binding of in vivo produced 
protein, we also compared binding of proteins expressed in HeLa cells (fig. 6c). This was 
an important question because Sox-11 may have post-translational modifications in vivo 
which affect DNA binding and are not present on in vitro translated protein. As described 
previously, in this DNA binding analysis, we normalized for any differences in protein 
expression by including equal amounts in the binding reactions, based on prior Western 
blot analysis (data not shown). Using extract containing Sox-11F, a faint DNA-protein com-
plex was observed (indicated by *), which could be supershifted specifically by the anti-
FLAG M2 antibody (lanes 4 and 5). In comparison, Sox-11FΔTAD binding resulted in two 
complexes (lane 6, single and double arrowheads), each of which was shifted specifically by 
the M2 antibody (lanes 7 and 8). The finding that the intensities of the Sox-11F and Sox-
11FΔTAD complexes were relatively similar suggests that the TAD of Sox-11F does little 
on its own to affect binding to DNA in vitro. Next, the role of the AR region of Sox-11 in 
binding to DNA was examined. Importantly, removal of this region resulted in the for-
mation of an intense, faster migrating complex (lane 9, double arrowhead) as well as a less 
intense, slower migrating complex (lane 9, single arrowhead). Both complexes were shifted 
specifically by the M2 antibody (lanes 10 and 11), indicating they each contain Sox- 
11FΔARΔTAD, although the supershift of the faster complex resulted in a smaller change 
in migration. This smaller shift was observed in multiple experiments and may indicate 
that either this antibody-Sox complex adopts a compact conformation, or perhaps it is de-
stabilized during electrophoresis, resulting in the release of the Sox protein from the anti-
body. The binding intensity of Sox-11FΔARΔTAD was estimated to be 10-fold greater than 
Sox-11F (as described under “Experimental Procedures”), indicating that this region acts 
strongly as a autoinhibitory domain. The significance of multiple DNA-protein complexes 
with Sox-11FΔARΔTAD and Sox-11FΔTAD is not clear at this time, but they do not alter 
the conclusion that a strong autoinhibitory region exists in Sox-11F. It is also interesting to 
note that in the case of both Sox-11F and Sox-11FΔTAD, the addition of the M2 antibody 
led to an increase in the intensity of the DNA-protein complex (compare lanes 3 and 4 or 
lanes 6 and 7), indicating that antibody binding may in some way neutralize the autoinhib-
itory region. We believe this further supports the hypothesis that an autoinhibitory region 
exists within Sox-11F because antibody binding has been found to release autoinhibition 
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in both PEA3 and p53 (34, 35). Taken together our findings suggest that a novel autoregu-
latory domain is present in Sox-11, which we suspect plays an important role in its function 
as a transcription factor in vivo. Furthermore, because autoinhibition occurs with both in 
vitro and in vivo produced protein it is most likely an intrinsic property of the protein rather 
than the result of post-translational modification or interaction with another factor. 
 
Influence of the Autoinhibitory Domain on Sox-11 Gene Activation 
Autoinhibitory domains present in other transcription factor families are thought to act as 
regulatory switches capable of repressing recruitment to a gene unless inhibition is re-
lieved. For example, the Ets family member PEA3 contains two domains that autoinhibit 
DNA binding to an optimized PEA3 binding site in vitro. Evidence that these autoinhibi-
tory domains also regulate in vivo recruitment of PEA3 was observed when the ability of 
full-length PEA3 to activate a reporter gene was compared with a deletion construct in 
which one autoinhibitory domain was removed. In these studies, removal of the autoin-
hibitory domain increased activation of the reporter gene ~2-fold, which indicates that the 
optimal capability of full-length PEA3 to activate gene expression was reduced (34). 
To examine whether the AR region can regulate the ability of Sox-11 to activate gene 
expression from transfected promoter/ reporter gene constructs, we compared Sox-11F and 
Sox-11FΔAR activation of reporter gene constructs. If the AR region of Sox-11F represses 
its DNA binding in vivo, its removal may enhance gene activation. Alternatively, because 
Sox-11F can clearly activate pCATSO3 in HeLa cells, autoinhibition may already be re-
lieved in vivo, and thus removal of the AR region may have no effect on Sox-11 activation. 
In these studies we examined the effect of the AR region on Sox-11 activation via two bona 
fide Sox target sequences, the FGF-4 HMG site as well as the HMG site present in the δ-
crystallin gene, hereafter referred to as the DC5 site. This site was chosen because it is less 
strongly activated by Sox-11 compared with the FGF-4 HMG site (36).2 The reporter con-
struct pCATDC3 was made to be identical to pCATSO3 with the exception of 3 bp within 
each of the six HMG binding sites to conform to the DC5 sequence. When observing the 
activation of pCATSO3 by Sox-11FΔAR compared with Sox-11F, we found that there was 
a reproducible 1.4–2-fold increase in activation when the AR region was absent (fig. 7a). 
Furthermore, the activation by Sox-11FΔAR compared with Sox-11F on pCATDC3 re-
vealed that the difference in gene activation was even more pronounced with this con-
struct, increasing in a dose-dependent manner to an almost 5-fold enhancement in gene 
activation upon removal of the AR region (fig. 7b). Finally, because both Sox-11FΔAR and 
Sox-11F are expressed at almost identical levels in HeLa cells (fig. 7c), expression differ-
ences do not explain the functional differences we are observing. Therefore, these studies 
support a model in which the ability of Sox-11 to bind to a gene and regulate its expression 
in vivo may be modulated by a acidic autoinhibitory domain. 
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Figure 7. The Sox-11 autoinhibitory domain represses gene activation in vivo. a and b, duplicate 
plates of HeLa cells were transfected with 5 μg of either pCATSO3 (a) or pCATDC3 (b) 
along with the indicated amounts of either Sox-11F or Sox-11FΔAR expression vector. The 
differences in amounts of Sox plasmid transfected with pCATSO3 compared with 
pCATDC3 were necessary because of the differing sensitivities of the reporter constructs 
to Sox-11 and were selected as the minimal amounts needed to achieve activation above 
the basal reporter gene expression. The number to the right of each bar represents the -fold 
difference in activation by Sox-11FΔAR compared with full-length Sox-11F at the same 
amount of transfected expression plasmid. All transfections included the empty CMV5 
plasmid to bring the final amount of DNA to 10 μg. CMV-β-gal was also included to nor-
malize for potential differences in transfection efficiency. Each experiment was repeated 
at least three times with a representative experiment shown. c, expression of Sox-11F and 
Sox-11FΔAR was determined by Western blot analysis of nuclear extracts obtained from 
transfected HeLa cells. The presence of each Sox protein was detected using the anti-
FLAG M2 antibody, visualized using ECF, and quantitated using a Storm PhosphorIm-
ager and ImageQuant 5.0 software. The molecular mass is shown on the left of the blot. 
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Discussion 
 
In this study, we compared the ability of Sox-2 and Sox-11 to activate expression of pro-
moter/reporter gene constructs via the HMG binding site found in the FGF-4 distal en-
hancer, which is a well-characterized regulatory element for studying the action of Sox 
proteins (15, 19, 20). This comparison has led to the identification of three Sox regulatory 
mechanisms, which together can regulate gene expression at multiple levels. First, we 
demonstrate that the transactivation domains of Sox-2 and Sox-11 are key determinants of 
their differential effects on transcription. Second, our study of Sox-POU partnerships 
demonstrates that the selection of Brn-2 by Sox-11 is determined by its HMG domain, high-
lighting the importance of this domain not only in DNA-protein interactions, but in protein-
protein interactions as well. Third, the identification of a novel autoinhibitory region 
within Sox-11 is an important advance in understanding how its binding to DNA may be 
regulated. These studies point to a model of Sox function in which DNA binding is not 
controlled by a single domain, but rather may be modulated by interplay with another 
region of the protein, leading to finely tuned gene activation. 
 
Function of Sox Proteins Is Highly Dependent on Their TADs 
Using a panel of Sox-2/11 chimeric proteins, we demonstrate that Sox-11 is a much more 
potent transcriptional activator than Sox-2 in the model system used in this study. A func-
tional comparison of these chimeras demonstrates that although the N-terminal and HMG 
domains modulate gene activation to a small extent, the primary region responsible for the 
potency of Sox-11 lies within its C-terminal TAD. In several cases, the potency of a TAD 
has been linked to its primary amino acid sequence. Domains that are rich in acidic and 
hydrophobic residues function differently in some contexts compared with those com-
posed of glutamine-, serine-, or proline-rich regions (37). We demonstrate that this pattern 
is also observed in our comparison of Sox-2, which has a serine/proline TAD, and Sox-11, 
which has a C terminus consisting of acidic and hydrophobic amino acids. Interestingly, 
Sox-4, Sox-22, and rainbow trout Sox-24 show high homology to the acidic TAD of Sox-11 
at their C terminus (38–40). This homology suggests that these proteins are also very strong 
transcriptional activators. In fact, we have determined that this is true of Sox-4, which we 
determined to be capable of 8–10-fold greater activation of the pCATSO3 promoter/re-
porter gene construct than Sox-2.2 These differences in transactivation potency within the 
Sox family provide a mechanism for altering gene expression through selective recruit-
ment of one Sox protein over another. 
 
Sox-POU Cooperation Is Selective and Dependent on the HMG Domain 
Although the study of a Sox factor on its own yields important insight into protein func-
tion, many Sox family members are influenced by other factors that bind DNA at adjacent 
sites. Specifically, Sox-2 and Sox-11 have been found to cooperate with the POU transcrip-
tion factors Oct-3 and Brn-2, respectively (15, 19, 20). The observation that partnerships 
between Sox and POU factors are not promiscuous, but rather are partner-specific has led 
to the hypothesis that a Sox-POU “code” exists which allows only some Sox-POU pairings 
to form productive complexes (20). Our studies give further credence to this hypothesis 
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because Sox-2 is capable of cooperating only with Oct-3 and not Brn-2. Additionally, Sox-
11 cooperates with Brn-2 (also shown in previous studies (20)) and Oct-3. 
The cooperative nature of Sox proteins has been found to require the HMG domain in 
multiple cases. Selective HMG-mediated interaction with another transcription factor has 
been observed on the FGF-4 enhancer where Sox-2 and Oct-3 have been shown to partner 
via their DNA binding domains (15, 16). The importance of Sox HMG domains has also 
been shown in the case of the δ-crystallin (DC5) enhancer, where either Sox-1 or Sox-2 can 
partner with the paired domain transcription factor Pax6 (29). On the DC5 enhancer, the 
partnership of Sox-1 or Sox-2 with Pax6 is specific to their HMG domains and cannot be 
satisfied by the HMG domain of Sox-9 (36). These examples indicate that although HMG 
domains exhibit the highest homology of any Sox domain, the minor differences that exist 
in this domain are capable of generating specific partnership interactions. Consistent with 
these precedents of HMG-mediated selection, we show here that the HMG domain of Sox-
11 is responsible for its ability to cooperate with Brn-2 because only Sox-11F and Sox-2-11-
2F can partner with Brn-2, whereas Sox-2F and Sox-11-2-11F cannot. Thus, there is growing 
support for a model in which the HMG domain serves two functions, DNA binding and 
partner selection, which may permit selective recruitment of Sox proteins only to specific 
genes. 
 
A Novel Autoinhibitory Region Is Present in Sox-11 
To expand our study of Sox-2 and Sox-11, we compared their ability to bind DNA in vitro. 
Using both in vivo and in vitro produced proteins, we demonstrate the formation of an 
intense Sox-2·DNA complex, whereas little or no binding of Sox-11 was detected, despite 
our use of the same amount of protein in the binding reaction. We also observed that Sox-
2-11-2F bound DNA with intensity similar to Sox-2, whereas in contrast Sox-11-2-11F was 
incapable of binding under these conditions. This suggests that the minimal HMG do-
mains of the two proteins are likely to bind DNA to a similar extent. The similar binding 
of Sox-2F and Sox-2-11-2F indicates that regions of Sox-11 beyond the HMG domain must 
influence DNA binding in vitro. Using a series of deletions constructs, we determined that 
a highly AR region within Sox-11 is capable of sharply repressing DNA binding by the 
Sox-11 HMG domain in vitro, identifying it as an autoinhibitory region. Importantly, the 
repression of DNA binding by the AR region is seen with in vitro produced protein as well 
as HeLa-derived proteins. This suggests that inhibition is an intrinsic property of the pro-
tein, rather than the result of post-translational modification or interaction with a repres-
sive factor present in HeLa extract. The AR region is particularly interesting because of its 
homology to Glu/Asp acid-rich stretches present in the HMG-1/2 proteins, which have 
been found to act as powerful negative regulators of DNA binding in those proteins as 
well (8, 41). Furthermore, the existence of acidic autoinhibitory regions has been reported 
in a wide range of transcription factors including RXR, Rfx1, E12, and Nkx6.1, although 
never before in a Sox protein (30–33). The importance of the acidic region within Sox-11 is 
highlighted by the fact that long acidic stretches are also present within other Sox family 
members, such as Sox-22 and Sox-24 (39, 40). Therefore, other Sox proteins may also con-
tain binding autoinhibitory regions. 
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There are several mechanisms through which binding autoregulatory regions may act. 
The functional and sequence similarities between the autoinhibitory region of Sox-11 and 
the extensively characterized acidic tails of chromosomal HMG proteins suggest that the 
two protein groups may be regulated by related mechanisms involving negative charge. 
This possibility is supported by a study of the repressive acidic tails of chromosomal HMG-
1 and HMG-2. It has been shown that the longer acidic tail of HMG-1 results in decreased 
ability to bind DNA compared with HMG-2 (41). These negatively charged autoinhibitory 
domains may be repulsed by the negative charge on the phosphate backbone of DNA or 
directly contact the positively charged HMG domain, resulting in a decreased affinity of 
the HMG domain for DNA. Indeed, in the case of HMG-1/2, it has been found that the 
negative acidic tail can interact directly with its HMG domain (42). It is possible that the 
autoinhibitory domain of Sox-11 acts similarly, perhaps by directly interacting with other 
domains of Sox-11 or by inducing conformation changes, resulting in decreased DNA 
binding as postulated in figure 8. 
 
 
 
Figure 8. Multiple levels of regulation impact Sox function. This model illustrates the regula-
tory mechanisms examined in this study which may influence Sox protein function. These 
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include autoinhibition as a mechanism for controlling DNA binding, which we hypothe-
size is the result of Sox-11 existing in either an active conformation or a repressed confor-
mation that requires the AR region of Sox-11. Additionally, selective partner interactions 
through the HMG domains of Sox-2 and Sox-11 can influence which POU proteins coop-
erate with Sox proteins in gene activation. Finally, if multiple Sox proteins are able to bind 
the same site, gene activation may be modulated through their differing transactivation 
capabilities. 
 
To permit DNA binding in vivo, autoinhibitory domains must be neutralized. This has 
been shown to occur through posttranslational modifications and/or direct interactions 
with partner proteins. Specifically, in the study of cooperative DNA binding between 
HMG-1 and the TATA-box binding protein, cooperation has been found to require the 
acidic tail of HMG-1 (11). This is not surprising because the hydrophilic nature of acidic 
autoinhibitory domains increases the likelihood that they are exposed at the surface of the 
protein, which places them in an ideal position to interact with other proteins. Addition-
ally, DNA binding of the maize chromosomal HMGB family can be regulated by phos-
phorylation of the acidic tail, indicating that acidic autoinhibitory regions can be regulated 
through multiple mechanisms (12). Other examples for such a model of transcription factor 
cooperation have also been found during the study of the autoinhibitory domains of Ets-1 
and PEA3, which are neutralized upon interaction with the transcription factors AML1 
and USF-1, respectively, thus enhancing DNA binding (9, 43). Similarly, the transcription 
factor LEF-1 contains an autoinhibitory domain, which is neutralized upon binding of the 
coactivator β-catenin, resulting in enhanced DNA binding (44). Interestingly, our promoter/ 
reporter gene activation studies indicate that the Sox-11 autoinhibitory domain may be at 
least partially neutralized in vivo because Sox-11 is able to bind DNA and transactivate 
when expressed in HeLa cells. Importantly, deletion of the AR inhibitory region leads to 
an ~2–5-fold boost in gene activation via two different promoter/reporter gene constructs, 
indicating that its autoinhibitory capacity is present in vivo and is capable of regulating 
gene expression. Based on the conservation of sequence and function between chromoso-
mal HMG proteins and Sox-11, it is plausible that the neutralization of the Sox-11 acidic 
autoinhibitory domain in the full-length protein may also occur through a number of com-
plex mechanisms, including posttranslational modification or interaction with other pro-
teins. 
In conclusion, this study makes several important contributions to the understanding 
of how Sox-2 and Sox-11 are regulated functionally, both on their own and in cooperation 
with other transcriptional regulators. We demonstrate that when the two proteins are com-
pared on their own, their transactivation domains play the primary role in determining 
their functional differences. However, in studying the selective partnership of Sox-11 and 
Brn-2, the HMG DNA binding domain was found to play a critical role. Building on the 
example observed in the Sox-2/Oct-3 partnership, this study provides further evidence that 
the Sox-POU code may depend on the DNA binding domains of these transcription factors. 
Finally, we have identified a novel autoinhibitory region within Sox-11 capable of signifi-
cantly influencing both DNA binding in vitro and gene expression in vivo. This observation 
places Sox-11 on an expanding list of transcription factors whose DNA binding appears to 
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be autoregulated by regions of the protein beyond the DNA binding domain. Furthermore, 
as the autoinhibitory region identified within Sox-11 shows homology to regions of other 
Sox proteins, this study suggests a similar mechanism may influence the function of sev-
eral other Sox family members. 
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Notes 
 
1. The abbreviations used are: HMG, high mobility group; AR, acid-rich; β-gal, β-galactosidase; 
CAT, chloramphenicol acetyltransferase; CMV, cytomegalovirus; DC5, δ-crystallin enhancer; 
ECF, enhanced chemifluorescence; EMSA, electrophoretic gel mobility shift analysis; FGF-4, fi-
broblast growth factor 4; POU, Pit-Oct-Unc; TAD, transactivation domain. 
2. M. Wiebe and A. Rizzino, unpublished observations. 
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